Jun 18, 2020 Press Release for Alnylam
Alnylam to Host Seventh Annual “RNAi Roundtable” Webcast Series
Jun 18, 2020
The initial 2020 RNAi Roundtable schedule will be as follows:
-
ALN-AGT, in Development for the Treatment of Hypertension
Tuesday, June 23 ,2:30 pm ET
-
Early Stage RNAi Therapeutics Pipeline
Friday, July 17 ,9:30 am ET
Additional RNAi Roundtables will be scheduled over the coming weeks, and will include:
- Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type 1
- Patisiran and Vutrisiran, in Development for the Treatment of ATTR Amyloidosis
- Givosiran, for the Treatment of Acute Hepatic Porphyria
Please visit the Capella section of our website for the latest information regarding webcast dates.
About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005426/en/
(Investors and Media)
617-682-4340
(Investors)
617-551-8276
Source:
For Media Inquiries, please contact:
Christine Lindenboom
SVP, Investor Relations & Corporate Communications media@alnylam.com 617-682-4340
For Investor Inquiries, please contact:
Josh Brodsky
VP, Investor Relations & Corporate Communications investors@alnylam.com 617-551-8276
MEDIA KIT
Essential assets and documents related to Alnylam